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This supplement of the British Journal of Cancer provides important
new information and commentary on survival rates for the 20 most
common cancers diagnosed in England and Wales over a 14-year
period from 1986 to 1999. The analyses are based on data collected by
cancer registries on 2.2 million cancer patients. The authors have
assessed both trends in survival rates over time and inequalities in
survival among groups of patients with different levels of deprivation,
based on the postcode of residence for individual patients.
A particular feature of this publication is that for each cancer
site the results and comments provided by epidemiologists are
accompanied by a commentary from one or more leading
clinicians. These clinical commentaries give insights into changes
in the diagnosis and treatment of the relevant cancers and possible
reasons for the changes observed over this time period.
Several key findings stand out from these papers:
 For most cancers, survival up to 10 years after diagnosis
improved significantly between patients diagnosed in the mid-
1980s and those diagnosed in the late 1990s. Marked improve-
ments were observed for three of the most common cancers
(breast, colorectal and prostate), though the remarkable
improvement in prostate cancer survival rates might be due
largely to improved case-finding.
 Important exceptions to this pattern of improved survival rates were
observed. There was almost no change in the survival rate for lung
cancer, pancreatic cancer and cervical cancer or bladder cancer.
 Survival rates were generally higher in more affluent than in
more deprived groups. However, exceptions to this pattern were
observed in the most recent time period (1996–1999) for brain
tumours in men and ovarian cancer in women.
 The deprivation gap widened for most cancers between the mid-
1980s and the late 1990s. It seems that more affluent groups
benefit sooner from improvements in diagnosis and/or survival.
However, deprivation gaps may be largely avoidable after a time
lag. Testicular cancer provides an interesting example of this.
Five-year relative survival rates in the most affluent groups were
near to reaching the ceiling of 100% by 1996–1999. Survival
rates for the most deprived groups seem to have been
catching up.
 For almost all cancer types, inequalities were observed within
1 year of diagnosis. This may provide an opportunity for earlier
monitoring of changes over time.
Interesting differences of opinion between epidemiologists and
clinical commentators emerge in relation to interpretation of the
reasons for the observed changes for several cancer types. In
general, clinicians were likely to attribute the deprivation gap
mainly to comorbidity. This interpretation is challenged by the
epidemiologists who put more emphasis on late diagnosis in
deprived groups as a cause for poorer survival.
These differences of opinion highlight the need for high-quality
information on staging and comorbidity to be collected by clinical
teams and to be transmitted to cancer registries. This is now being
given high priority in England through the Cancer Reform
Strategy. Understanding of the underlying reasons for the
deprivation gaps is urgently needed so that NHS resources can
be targeted most effectively.
Finally, these reports highlight the importance of comprehensive
cancer registration to monitor cancer outcomes and as a tool for
investigating the mechanisms underlying changes over time. To
achieve the maximum benefit, clinicians and epidemiologists need
to work in close partnership. This will be a major feature of the
newly established National Cancer Intelligence Network in the
United Kingdom.
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